SNC 112
Alternative Names: BCMA/GPRC5D targeting CAR NK cell therapy - Shanghai Simnova Biotechnology; BCMA/GPRC5D targeting chimeric antigen receptor NK cell therapy - Shanghai Simnova Biotechnology; SNC-112Latest Information Update: 21 Jul 2025
At a glance
- Originator Shanghai Simnova Biotechnology
- Developer Shanghai Simnova Biotechnology; Simcere Zaiming
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; Natural killer T cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple myeloma